Needham Reiterates Buy on Gilead Sciences, Maintains $170 Price Target
Gilead Sciences, Inc. -0.87%
Gilead Sciences, Inc. GILD | 138.55 | -0.87% |
Needham analyst Joseph Stringer reiterates Gilead Sciences (NASDAQ:
GILD) with a Buy and maintains $170 price target.
